Skip to main content

Table 1 Demographic and clinical characteristics of the total study population and the four study groups

From: Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients

  

All patients

No cART

cART/no TFV

cART/TFV

p-value

TFV/NNRTI

TFV/PI

p-value

Number of patients

N (% of total)

317 (100)

57 (18)

143 (45)

117 (37)

 

72 (23)

45 (14)

 

Age (years)

Mean (SD) (range)

41.0 (8.9) (24.4, 64.3)

38.0 (8.5) (21.2, 60.2)

40.9 (8.9) (25.8, 63.3)

42.3 (8.8) (25.7, 70.1)

0.83

42.3 (9.3) (21.7, 65.8)

42.6 (7.3) (27.5, 63.3)

0.30

Male gender

N (%)

222 (70)

43 (75)

89 (62)

90 (77)

0.02

54 (75)

36 (80)

0.53

Black Ethnicity

N (%)

189 (60)

31 (54)

95 (66)

63 (54)

0.08

35 (49)

28 (62)

0.15

Time since HIV diagnosis (years)

Median (IQR)

4.9 (2.1, 8.7)

2.0 (0.5, 4.2)

5.1 (2.2, 8.2)

5.8 (3.1, 4.7)

0.0001

5.1 (2.5, 8.2)

7.8 (4.1, 11.4)

0.003

Time since start cART (years)

Median (IQR)

4.6 (2.6, 7.6)

3.2 (2.6, 5.9)

4.3 (2.6, 6.8)

4.8 (2.6, 8.1)

0.51

4.5 (2.5, 7.3)

6.0 (3.1, 9.2)

0.009

AIDS (CDC status C)

(N, %)

77 (17)

1 (2)

27 (19)

33 (28)

<0.0001

17 (24)

16 (35)

0.16

Nadir CD4 count (cells/mm3)

Median (IQR)

171 (71, 262)

290 (230, 416)

161 (69, 250)

146 (64, 210)

0.0001

158 (82, 224)

94 (25, 222)

0.07

Current CD4 count (cells/mm3)

Median (IQR)

389 (270, 532)

437 (329, 560)

363 (269, 534)

385 (259, 517)

0.13

385 (245, 512)

376 (249, 566)

0.62

Current HIV RNA (log10)

Mean (SD)

2.4 (1.3)

3.9 (1.1)

2.2 (1.1)

2.0 (1.0)

0.0001

2.1 (1.1)

2.1 (1.0)

0.04

HIV RNA <50 c/mL

N (%)

204 (65)

4 (9)

110 (77)

90 (77)

<0.0001

60 (83)

30 (67)

<0.0001

Hepatitis B surface Ag (positive)

N (%)

15 (5)

3 (5)

4 (3)

8 (7)

0.31

4 (6)

4 (9)

0.49

Hepatitis C Antibody (positive)

N (%)

20 (6)

3 (5)

3 (2)

14 (12)

0.005

10 (14)

4 (9)

0.42

eGFR (mL/min/1.73 m2)

Median (IQR)

89 (78, 99)

91 (81, 99)

89 (80, 100)

85 (77, 97)

0.08

86 (76, 97)

82 (76, 96)

0.84

Diabetes

N (%)

11 (4)

0 (0)

7 (6)

4 (4)

0.27

2 (3)

2 (5)

0.62

Hypertension

N (%)

39 (15)

5 (12)

20 (16)

14 (13)

0.75

11 (17)

3 (8)

0.16

Weight (Kg)

Median (IQR)

74.2 (66.0, 82.0)

76.0 (68.9, 85.0)

74.3 (65.6, 82.0)

73.5 (66.0, 82.9)

0.39

73.6 (66.4, 81.0)

71.1 (65.6, 84.9)

0.73

BMI

Median (IQR)

24.6 (22.9, 28.1)

25.6 (22.5, 31.4)

25.5 (22.4, 29.6)

23.9 (21.9, 27.1)

0.06

24.1 (22.1, 26.8)

23.5 (21.4, 27.7)

0.73

  1. p value for comparison between study groups (significance relates to the group in bold).
  2. cART = combination antiretroviral therapy; TFV = tenofovir; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; eGFR = estimated glomerular filtration rate; BMI = body mass index.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us